莱斯康制药(LXRX.US)盘中一度飙升101.15%,报0.7美元。消息面上,公司宣布与诺和诺德(NVO.US)达成独家许可协议,合作开发其肥胖症候选药物LX9851。根据协议,莱斯康制药将获得7500万美元的前期和近期里程碑付款,而诺和诺德则获得LX9851的全球独家开发、制造和商业化权利,用于治疗肥胖症及相关代谢紊乱。此外,莱斯康制药还有望获得最高达10亿美元的前期及潜在开发、监管和销售...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.